Ovarian cancer screening would be feasible in primary care, according to the early results of a major Department of Health, UK funded analysis. – Blood test combined with ultrasound scan can diagnose ovarian cancer (gynecological cancer) early in postmenopausal women, almost 2 years earlier than normal, reported by the British researchers in the Lancet.
Red wine vs. white? It makes no difference when it comes to breast-cancer risk – The largest study of its kind to evaluate the effect of red versus white wine on breast-cancer risk concludes that both are equal offenders when it comes to increasing breast-cancer risk.
Long-term multivitamin use has no impact on the risk of common cancers, cardiovascular disease or overall mortality in postmenopausal women. – The largest study ever conducted on postmenopausal women shows that multivitamins may offer no benefit in reducing the risk of common cancers, cardiovascular disease or overall mortality.
Reduced breast cancer risk: Physical activity after menopause pays off – Several studies had previously suggested that regular physical exercise reduces the breast cancer risk of women. However, it had been unknowned just how much exercise women should take in which period in life in order to benefit from this protective effect.
Study links obese women are at an increased risk of developing ovarian cancer compared with women of normal weight. – A new epidemiological study has found that among women who have never used menopausal hormone therapy, obese women are at an increased risk of developing ovarian cancer compared with women of normal weight.
Long term use of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes. – Long term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes, revealed by researchers at the Wake Forest University School of Medicine and the University of East Anglia.
Taking calcium and vitamin D supplements does not lower a woman?s risk of breast cancer, according to a randomized controlled trial. – Taking calcium and vitamin D supplements does not reduce breast cancer incidence in postmenopausal women, according to data from a randomized, doubled-blind, placebo-controlled trial published online November 11 in the Journal of the National Cancer Institute.
Vigorous activity protects against breast cancer, women 30% less likely to develop breast cancer. – Normal-weight women who carry out lots of vigorous exercise are approximately 30% less likely to develop breast cancer than those who don’t exercise vigorously.
An experimental Merck & Co. osteoporosis drug improved bone strength in postmenopausal women after two years of treatment with Odanacatib. – 2 year data from a Phase IIB study of odanacatib (formerly MK-0822), an investigational, selective cathepsin-K inhibitor in development for the treatment of osteoporosis by Merck & Co., Inc., demonstrated dose-dependent increases in bone mineral density (BMD) at the total hip, lumbar spine and femoral neck fracture sites and decreased indices of bone resorption compared to placebo in postmenopausal women with low BMD.
Women who survive five years after being diagnosed with breast cancer and after adjuvant systemic therapy have a good chance of remaining cancer free. – Breast cancer survivors continue to have a substantial risk of disease recurrence after five years of systemic therapy, according to a study published in the August 12 online issue of the Journal of the National Cancer Institute.
Difficulty falling asleep and staying asleep increases as women go through menopause, revealed by researchers. – Sleep difficulties, especially problems staying asleep, are relatively prevalent concerns among women going through the menopausal transition, revealed by researchers at Rush University Medical Center in Chicago.
Hormone replacement therapy (HRT) for peri- and postmenopausal symptoms increases disease recurrence in breast cancer survivors. – A new study HABITS revealed that breast cancer survivors who took hormone replacement therapy (HRT) for peri- and postmenopausal symptoms increases disease recurrence than those who did not take HRT.
